AR091027A1 - Analogos de benzomorfano y el usos de estos - Google Patents

Analogos de benzomorfano y el usos de estos

Info

Publication number
AR091027A1
AR091027A1 ARP130101641A ARP130101641A AR091027A1 AR 091027 A1 AR091027 A1 AR 091027A1 AR P130101641 A ARP130101641 A AR P130101641A AR P130101641 A ARP130101641 A AR P130101641A AR 091027 A1 AR091027 A1 AR 091027A1
Authority
AR
Argentina
Prior art keywords
alkyl
elements
halo
coor7
cycloalkyl
Prior art date
Application number
ARP130101641A
Other languages
English (en)
Inventor
Tafesse Laykea
Hyun Park Jae
Yu Jianming
Rosen David
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of AR091027A1 publication Critical patent/AR091027A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Compuestos análogos de benzomorfano de la fórmula --------- en donde R1, R2a, R2b, R3, R4, Z y G son como se definen en la presente. Los compuestos son útiles para tratar dolor, constipación y otras condiciones moduladas por la actividad de los receptores opioides y ORL-1. Reivindicación 1: Un compuesto de la fórmula (1), en donde R¹ se elige del grupo que consiste en -alquilo C₁₋₁₀, -alquenilo C₂₋₁₀, -alquinilo C₂₋₁₀, -cicloalquilo C₃₋₁₂, cicloalquil C₃₋₁₂-alquilo C₁₋₆, -cicloalquenilo C₃₋₁₂, cicloalquenil C₃₋₁₂-alquilo C₁₋₆, -arilo (de 6 a 14 elementos), (arilo (de 6 a 14 elementos))-alquilo C₁₋₆, -(OCH₂CH₂)ₛ-O-alquilo C₁₋₆, -(CH₂CH₂O)ₛ-alquilo C₁₋₆, alcoxi C₁₋₁₀, C₍ₕₐₗₒ₎₃, CH(halo)₂, CH₂(halo), C(O)R⁵, C(O)O-alquilo C₁₋₁₀, y -(CH₂)ₙ-N(R⁶)₂, en donde cada uno es sustituido opcionalmente por 1, 2 ó 3 R⁹ grupos seleccionados de manera independiente; R²ᵃ y R²ᵇ son, cada uno, seleccionados de manera independiente de: (a) -H; o (b) -alquilo C₁₋₅, -alquenilo C₂₋₅, o -alquinilo C₂₋₅; Z está ausente o -(CH₂)ₘ-, opcionalmente sustituido por 1 ó 2 -alquilo C₁₋₆ elegidos en forma independiente; G se elige del grupo que consiste en: e) un enlace, -alquileno C₁₋₆, -alquenileno C₂₋₆; o f) O, -OCO-, -C(=O); o g) NR⁸; o h) S, SO y SO₂; R³ se elige del grupo que consiste en hidrógeno, -alquilo C₁₋₁₀, -alquenilo C₂₋₁₂, -C(=O), C(=O)-alquilo C₁₋₆, -C(=O)-alquilo C₁₋₆, -C(=O)-arilo (de 6 a 14 elementos), -C(=O)-heteroarilo (de 5 a 12 elementos), -alquinilo C₂₋₁₂, -alcoxi C₁₋₁₀, -(OCH₂CH₂)ₛ-O-alquilo C₁₋₆, -(CH₂CH₂O)ₛ-alquilo C₁₋₆, -NH₂, -NH-alquilo C₁₋₆, CN, -CONR⁵R⁶, -alquilo C₁₋₆CONR⁵R⁶, -COOR⁷, -alquil C₁₋₆-COOR⁷, -alcoxi C₁₋₆-COOR⁷, -C(=O)-(CH₂)ₙ-COOR⁷, -C(=O)-(CH₂)ₙ-CONR⁵R⁶, -cicloalquilo C₃₋₁₂, (cicloalquilo C₃₋₁₂)-alquilo C₁₋₆, -cicloalquenilo C₄₋₁₂, (cicloalquenilo C₄₋₁₂)-alquilo C₁₋₆, -bicicloalquilo C₆₋₁₄, (bicicloalquilo C₆₋₁₄)-alquilo C₁₋₆, -tricicloalquilo C₅₋₂₀, (tricicloalquilo C₈₋₂₀)-alquilo C₁₋₆, -bicicloalquenilo C₇₋₁₄, (bicicloalquenilo C₇₋₁₄)-alquilo C₁₋₆, -tricicloalquenilo C₈₋₂₀, (tricicloalquenilo C₈₋₂₀)-alquilo C₁₋₆, -arilo (de 6 a 14 elementos), (arilo (de 6 a 14 elementos))-alquilo C₁₋₆, -sistema de anillo bicíclico (de 7 a 12 elementos), (sistema de anillo bicíclico (de 7 a 12 elementos))-alquilo C₁₋₆, -arilo bicíclico (de 7 a 12 elementos), (arilo bicíclico (de 7 a 12 elementos))-alquilo C₁₋₆, -heteroarilo (de 5 a 12 elementos), (heteroarilo (de 5 a 12 elementos))-alquilo C₁₋₆, -heterociclo (de 3 a 12 elementos), (heterociclo (de 3 a 12 elementos))-alquilo C₁₋₆, -bicicloheterociclo (de 7 a 12 elementos), (bicicloheterociclo (de 7 a 12 elementos))-alquilo C₁₋₆, fenilo, bencilo y naftilo; en donde cada uno es opcionalmente sustituido por uno, dos o tres sustituyentes seleccionados de manera independiente del grupo que consiste en -OH, (=O), halo, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -alquilo C₁₋₆, haloalquilo C₁₋₆, -alquenilo C₂₋₆, -alquinilo C₂₋₆, hidroxialquilo C₁₋₆, dihidroxialquilo C₁₋₆, -alcoxi C₁₋₆, (alcoxi C₁₋₆)-C(=O)-alcoxi C₁₋₆-, fenilo, bencilo, -NH₂, -NR⁵R⁶, -NH-alquilo C₁₋₆, -alquil C₁₋₆-NH-alquil C₁₋₆-R¹⁴, -CN, -SH, -OR⁴, -CONR⁵R⁶, -(alquilo C₁₋₆)-C(=O)-NR⁵R⁶, -COOR⁷, -alquil C₁₋₆-COOR⁷, -alcoxi C₁₋₆-COOR⁷, -(OCH₂CH₂)ₛ-O-alquilo C₁₋₆, -(CH₂CH₂O)ₛ-alquilo C₁₋₆, (alquilo C₁₋₆)sulfonil-alquilo C₁₋₆, -NH-SO₂-alquilo C₁₋₆, -N-(SO₂-alquilo C₁₋₆)₂, -C(=NH)-NH₂, -NH-C(=O)-alquilo C₁₋₆, -NH-C(=O)-NH₂, -NH-C(=O)-NH-alquilo C₁₋₆, -NH-C(=O)-arilo (de 6 a 14 elementos), -NH-C(=O)-alquil C₁₋₆-arilo (de 6 a 14 elementos), -NH-alquil C₁₋₆-COOR⁷, -NH-C(=O)-alquil C₁₋₆-COOR⁷, -NH-C(=O)-CH(NH₂)-alquil C₁₋₆-C(=O)-OR⁷, -cicloalquilo C₃₋₁₂, (cicloalquilo C₃₋₁₂)-alquilo C₁₋₆, -arilo (de 6 a 14 elementos), -ariloxi (de 6 a 14 elementos), -alcoxi C₁₋₆C₍₌O₎NR⁵R⁶, -NH-alquilo C₁₋₆-C(O)-NR⁵R⁶, -C(O)NH-alquil C₁₋₆-COOR⁷, (arilo (de 6 a 14 elementos))-alquilo C₁₋₆, -heteroarilo (de 5 a 12 elementos), (heteroarilo (de 5 a 12 elementos))-alquilo C₁₋₆, -heterociclo (de 3 a 12 elementos), (heterociclo (de 3 a 12 elementos))-alquilo C₁₋₆, -bicicloheterociclo (de 7 a 12 elementos), y (bicicloheterociclo (de 7 a 12 elementos))-alquilo C₁₋₆; R⁴ se elige de (c) -H, -OH, halo, -C(halo)₃, -CH(halo)₂, -CH₂(halo), COOH, o CONH₂; o (d) -alquilo C₁₋₅, -alquenilo C₂₋₅, -alquinilo C₂₋₅, -(CH₂)ₙ-O-(CH₂)ₙ-CH₃, o -alcoxi C₁₋₅, en donde cada uno es opcionalmente sustituido por 1, 2 ó 3 grupos R⁹ seleccionados de manera independiente; R⁵ y R⁶ son, cada uno, seleccionados de manera independiente de (e) hidrógeno, -OH, halo, -C(halo)₃, -CH(halo)₂, -CH₂(halo); o (f) -alquilo C₁₋₆, -alquenilo C₂₋₅, -alquinilo C₂₋₅, -(CH₂)ₙ-O-(CH₂)ₙ-CH₃, -alcoxi C₁₋₆, en donde cada uno es opcionalmente sustituido por 1, 2 ó 3 grupos R⁹ seleccionados de manera independiente; o (g) -cicloalquilo C₃₋₈, (cicloalquilo C₃₋₈)-alquilo C₁₋₆, -COOR⁷, -alquil C₁₋₆-COOR⁷, -CONH₂, o alquil C₁₋₆-CONH-; o (h) R⁵ y R⁶ junto con el átomo de nitrógeno al que están unidos forman un heterociclo (de 4 a 8 elementos); R⁷ se elige del grupo que consiste en hidrógeno, -alquilo C₁₋₆, -alquenilo C₂₋₆, -alquinilo C₂₋₆, -cicloalquilo C₃₋₁₂, -cicloalquenilo C₄₋₁₂, (cicloalquilo C₃₋₁₂)-alquilo C₁₋₆, y (cicloalquenilo C₄₋₁₂)-alquilo C₁₋₆; R⁸ se elige de H, -alquilo C₁₋₆, -alquenilo C₂₋₆, -alquinilo C₂₋₆, -alcoxi C₁₋₁₀, -cicloalquilo C₃₋₁₂, -cicloalquenilo C₃₋₁₂, (cicloalquilo C₃₋₁₂)-alquilo C₁₋₆, (cicloalquenilo C₃₋₁₂)-alquilo C₁₋₆, -C(=O)alquilo C₁₋₆ o SO₂-alquilo C₁₋₆; cada R⁹ es seleccionado de manera independiente de -OH, halo, -alquilo C₁₋₁₀, -alquenilo C₂₋₁₀, -alquinilo C₂₋₁₀, -alcoxi C₁₋₁₀, -cicloalquilo C₃₋₁₂, -CHO, -C(O)OH, -C(halo)₃, -CH(halo)₂, CH₂(halo), o -(CH₂)ₙ-O-(CH₂)ₙ-CH₃; cada R¹⁴ se elige en forma independiente del grupo que consiste en -COOR⁷, -alquil C₁₋₆-COOR⁷, -C(=O)-alquil C₁₋₆-COOR⁷, -alquil C₁₋₆-C(=O)-alquil C₁₋₆-COOR⁷, CONH₂, y -alquil C₁₋₆-CONH; m es un entero 1, 2, 3, 4, 5 ó 6; n es un entero 0, 1, 2, 3, 4, 5 ó 6; s es un entero 1, 2, 3, 4, 5 ó 6; y las sales y so
ARP130101641A 2012-05-11 2013-05-10 Analogos de benzomorfano y el usos de estos AR091027A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261646068P 2012-05-11 2012-05-11
US201361778091P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
AR091027A1 true AR091027A1 (es) 2014-12-30

Family

ID=48577149

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101641A AR091027A1 (es) 2012-05-11 2013-05-10 Analogos de benzomorfano y el usos de estos

Country Status (7)

Country Link
US (2) US20150210646A1 (es)
EP (1) EP2858976B1 (es)
JP (1) JP6114382B2 (es)
AR (1) AR091027A1 (es)
CA (1) CA2870605A1 (es)
TW (1) TW201408645A (es)
WO (1) WO2013167963A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0632938Y2 (ja) 1988-07-20 1994-08-31 株式会社神戸製鋼所 クレーンの旋回制御装置
CA2810356C (en) 2010-09-21 2016-06-14 Purdue Pharma L.P. Buprenorphine analogs
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
EP2931729B1 (en) 2012-12-07 2019-02-06 Purdue Pharma LP Buprenorphine analogs as opiod receptor modulators
WO2014091297A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Spirocyclic morphinans and their use
ES2631197T3 (es) 2012-12-14 2017-08-29 Purdue Pharma Lp Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
CA2900023A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US9688638B2 (en) 2013-11-27 2017-06-27 Nektar Therapeutics Opioid agonists and uses thereof
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
US9656962B2 (en) 2013-12-26 2017-05-23 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
US9975854B2 (en) * 2014-05-06 2018-05-22 Purdue Pharma L.P. Benzomorphan analogs and use thereof
EP3148535A4 (en) 2014-05-27 2017-11-29 Purdue Pharma LP Spirocyclic morphinans and use thereof
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
WO2016044546A1 (en) * 2014-09-17 2016-03-24 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
US20220289748A1 (en) 2019-07-19 2022-09-15 Nippon Chemiphar Co., Ltd. Method for producing phenol derivative
CN119977886B (zh) * 2025-02-13 2025-08-22 安徽益普克医药科技发展有限公司 一种葡萄糖酸喷他佐辛苯甲酸酯及其制备方法与用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3480638A (en) * 1966-11-10 1969-11-25 Geigy Chem Corp Derivatives of 5-hydroxyalkyl-6,7-benzomorphans
US3480338A (en) * 1967-11-13 1969-11-25 Caterpillar Tractor Co Seals for track link assemblies
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3883536A (en) * 1970-05-27 1975-05-13 Acf Chemiefarma Nv 3,3-Disubstituted-2-benzyl-4-piperidinols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3891657A (en) * 1972-10-26 1975-06-24 Bristol Myers Co 9Beta-hydroxy-5-methyl-6,7-benzomorphans
US3853887A (en) * 1973-03-09 1974-12-10 Universal Oil Prod Co Cyclialkylation of amines
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3932422A (en) * 1974-05-20 1976-01-13 Sterling Drug Inc. 8-Methylene-3-azabicyclo[3.3.1]non-6-en-4-ones
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
NL7907800A (nl) 1979-10-23 1981-04-27 Acf Chemiefarma Nv Nieuwe 6,7-benzomorfanderivaten en zuuradditiezouten daarvan, farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werkwijze voor het bereiden van deze verbindingen en de farmaceutische preparaten.
DE2943805A1 (de) 1979-10-30 1981-05-27 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 3-phenoxy-benzaldehyden
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1996041626A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6258825B1 (en) 1997-05-30 2001-07-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
HUP0101275A3 (en) 1998-03-26 2002-12-28 Japan Tobacco Inc Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
DE19826365A1 (de) * 1998-06-12 1999-12-16 Gruenenthal Gmbh Verwendung von Benzomorphanderivaten als Analgetikum
EP2620437A1 (en) * 2007-11-30 2013-07-31 Purdue Pharma LP Benzomorphan compounds
ATE531696T1 (de) * 2008-02-12 2011-11-15 Boehringer Ingelheim Int Harnstoff-derivate von benzomorphanen, entsprechende gerüste, medikamente mit solchen verbindungen und ihre verwendung
US9975854B2 (en) * 2014-05-06 2018-05-22 Purdue Pharma L.P. Benzomorphan analogs and use thereof

Also Published As

Publication number Publication date
US20180127374A1 (en) 2018-05-10
EP2858976B1 (en) 2018-03-14
US20150210646A1 (en) 2015-07-30
WO2013167963A1 (en) 2013-11-14
TW201408645A (zh) 2014-03-01
EP2858976A1 (en) 2015-04-15
JP2015516410A (ja) 2015-06-11
JP6114382B2 (ja) 2017-04-12
CA2870605A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
AR094641A1 (es) Análogos de buprenorfina
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR087127A1 (es) Compuestos que se unen a fxr (nr1h4) y modulan su actividad
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
AR072249A1 (es) Inhibidores de amida hidrolasa de acido graso. usos. metodos.
AR090548A1 (es) Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR114417A1 (es) Compuestos y métodos de uso
AR088061A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
AR062011A1 (es) Derivados de diazol y sus composiciones como inhibidores de itpkb
AR100244A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
AR094646A1 (es) Morfinanos sustituidos y su uso
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
BR112015015812A2 (pt) derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor
AR094929A1 (es) Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
AR086792A1 (es) Compuestos para el tratamiento de la adiccion
AR091022A1 (es) Inhibidores del nampt
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
AR079636A1 (es) Antagonistas del receptor ccr2 y usos de los mismos
AR093504A1 (es) 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos
AR090293A1 (es) Inhibidores de quinasa a base de arileter
AR099914A1 (es) Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR092288A1 (es) Ligandos del receptor ep1
AR112468A1 (es) Carboxamidas como inhibidores de proteasa específicos de ubiquitina
AR088320A1 (es) Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt
AR121296A1 (es) Moduladores de monoacilglicerol lipasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure